Jazz Pharmaceuticals plc United Kingdom Ireland

Ireland +353 1 634 3211
U.S. +1 650 496 2717

Jazz Media Contact:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

Redx Contacts:
Caitlin Pearson
Head of Communications
Redx Pharma
UK +44 (0)1625 469 918

Matt Davis/ Adam Dawes
SPARK Advisory Partners (Nominated Adviser)
UK +44 (0)203 368 3550

Claes Spång/ Satheesh Nadarajah/ David Wilson
WG Partners LLP (Joint Broker)
UK +44 (0)203 705 9330

Rupert Dearden/Freddy Crossley/Emma Earl
Panmure Gordon (UK) Limited (Joint Broker)
UK +44 (0)207 886 2500

Simon Conway/Ciara Martin
FTI Consulting
UK +44 (0)203 727 1000

 

Logo - https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_New_Logo.jpg

Logo - https://mma.prnewswire.com/media/2335760/Redx_Logo_Master_Colour_CMYK_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-enters-definitive-agreement-with-redx-pharma-to-acquire-global-rights-to-kras-inhibitor-program-302055498.html